Roche Holding AG

Roche Holding AG Earnings Recaps

ROP.SW 1 recap
Q2 2026 Jul 25, 2026

Roche’s shares gained 6.8% post-earnings, reflecting upbeat core operating profit growth and margin expansion that outpaced sales growth, supported by strong pipeline progress and regulatory milestones.

Key takeaways
  • Core operating profit rose 10%, outstripping sales growth of 6%, resulting in a 1.7 percentage point increase in the core operating margin.
  • Core EPS increased by 9%, with strong contributions from both pharma (6% growth) and diagnostics (3% growth, or 7% excluding China impact and flu season effects).
  • Regulatory advancements included five U.S. FDA priority reviews for Tecentriq and Gazyva, alongside positive Phase III trial results supporting an 80% success rate this year.
  • The company highlighted disciplined business development deals and a rich late-stage pipeline with multiple upcoming Phase III readouts and new molecular entity launches through 2029.
  • Diagnostic segment progress included recent acquisitions and product launches that are expected to contribute to sustained growth despite healthcare pricing reforms and seasonal headwinds.
Full recap

Go deeper on ROP.SW and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.